Syneron Bio closed a $150 million Series B to support its macrocyclic peptide development platform, following a multibillion-dollar biobucks deal with AstraZeneca and nearly $100 million raised earlier. The funding underscores investor confidence in peptide platforms positioned for difficult targets that may benefit from constrained macrocyclic architectures. In a separate funding milestone, Ambrosia Biosciences secured an oversubscribed $100 million Series B to advance its oral small-molecule GLP-1 obesity pipeline toward Phase I, co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Both announcements point to parallel capital flows into modalities—peptides and oral incretin small molecules—that are designed to improve efficacy or patient convenience, respectively.